Gavin W. G. Wilkinson

Gavin W. G. Wilkinson

Auto-generated profile, based on publicly available information

Gavin W. G. Wilkinson

Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2004 in Journal of General Virology
Verified
Journal Article
Open access
ADAidan Dolan
Aidan Dolan
CCCharles Cunningham
Charles Cunningham
RHRalph Hector
Ralph Hector
AHAycan F. Hassan-Walker
Aycan F. Hassan-Walker
LLLydia Lee
Lydia Lee
ADAndrew J. Davison
Andrew J. Davison
The genetic content of wild-type human cytomegalovirus was investigated by sequencing the 235 645 bp genome of a low passage strain (Merlin). Substantial regions of the genome (genes RL1–UL11, UL105–UL112 and UL120–UL150) were also sequenced in several other strains, including two that had not been passaged in cell culture. Comparative analyses, which employed the published genome sequence of a high passage strain (AD169), indicated that Merlin accurately reflects the wild-type complement of 165 genes, containing no obvious mutations other than a single nucleotide substitution that truncates gene UL128. A sizeable subset of genes exhibits unusually high variation between strains, and comprises many, but not all, of those that encode proteins known or predicted to be secreted or membrane-associated. In contrast to unpassaged strains, all of the passaged strains analysed have visibly disabling mutations in one or both of two groups of genes that may influence cell tropism. One comprises UL128, UL130 and UL131A, which putatively encode secreted proteins, and the other contains RL5A, RL13 and UL9, which are members of the RL11 glycoprotein gene family. The case in support of a lack of protein-coding potential in the region between UL105 and UL111A was also strengthened.

1 June 2014 in Cell
Verified
Journal Article
Open access
MWMichael P. Weekes
Michael P. Weekes
PTPeter Tomasec
Peter Tomasec
EHEdward L. Huttlin
Edward L. Huttlin
CFCeri Alan Fielding
Ceri Alan Fielding
DNDavid Nusinow
David Nusinow
SGSteven P. Gygi
Steven P. Gygi
A systematic quantitative analysis of temporal changes in host and viral proteins throughout the course of a productive infection could provide dynamic insights into virus-host interaction. We developed a proteomic technique called "quantitative temporal viromics" (QTV), which employs multiplexed tandem-mass-tag-based mass spectrometry. Human cytomegalovirus (HCMV) is not only an important pathogen but a paradigm of viral immune evasion. QTV detailed how HCMV orchestrates the expression of >8,000 cellular proteins, including 1,200 cell-surface proteins to manipulate signaling pathways and counterintrinsic, innate, and adaptive immune defenses. QTV predicted natural killer and T cell ligands, as well as 29 viral proteins present at the cell surface, potential therapeutic targets. Temporal profiles of >80% of HCMV canonical genes and 14 noncanonical HCMV open reading frames were defined. QTV is a powerful method that can yield important insights into viral infection and is applicable to any virus with a robust in vitro model.

1 June 1996 in The Lancet
Verified
Journal Article
Closed access
LBL.K Borysiewicz
L.K Borysiewicz
AFA Fiander
A Fiander
MNM Nimako
M Nimako
SMS Man
S Man
GWG.W.G Wilkinson
G.W.G Wilkinson
SIS.C Inglis
S.C Inglis

1 September 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RSRichard Stanton
Richard Stanton
KBKatarina Baluchova
Katarina Baluchova
DDDerrick J. Dargan
Derrick J. Dargan
CCCharles Cunningham
Charles Cunningham
OSOrla Sheehy
Orla Sheehy
GWGavin W.G. Wilkinson
Gavin W.G. Wilkinson
Human cytomegalovirus (HCMV) in clinical material cannot replicate efficiently in vitro until it has adapted by mutation. Consequently, wild-type HCMV differ fundamentally from the passaged strains used for research. To generate a genetically intact source of HCMV, we cloned strain Merlin into a self-excising BAC. The Merlin BAC clone had mutations in the RL13 gene and UL128 locus that were acquired during limited replication in vitro prior to cloning. The complete wild-type HCMV gene complement was reconstructed by reference to the original clinical sample. Characterization of viruses generated from repaired BACs revealed that RL13 efficiently repressed HCMV replication in multiple cell types; moreover, RL13 mutants rapidly and reproducibly emerged in transfectants. Virus also acquired mutations in genes UL128, UL130, or UL131A, which inhibited virus growth specifically in fibroblast cells in wild-type form. We further report that RL13 encodes a highly glycosylated virion envelope protein and thus has the potential to modulate tropism. To overcome rapid emergence of mutations in genetically intact HCMV, we developed a system in which RL13 and UL131A were conditionally repressed during virus propagation. This technological advance now permits studies to be undertaken with a clonal, characterized HCMV strain containing the complete wild-type gene complement and promises to enhance the clinical relevance of fundamental research on HCMV.

1 June 2007 in Science
Verified
Journal Article
Open access
PDF file
MRMatthew B Reeves
Matthew B Reeves
ADAndrew A. Davies
Andrew A. Davies
BMBrian McSharry
Brian McSharry
GWGavin W. Wilkinson
Gavin W. Wilkinson
JSJohn H. Sinclair
John H. Sinclair
Human cytomegalovirus infection perturbs multiple cellular processes that could promote the release of proapoptotic stimuli. Consequently, it encodes mechanisms to prevent cell death during infection. Using rotenone, a potent inhibitor of the mitochondrial enzyme complex I (reduced nicotinamide adenine dinucleotide–ubiquinone oxido-reductase), we found that human cytomegalovirus infection protected cells from rotenone-induced apoptosis, a protection mediated by a 2.7-kilobase virally encoded RNA (β2.7). During infection, β2.7 RNA interacted with complex I and prevented the relocalization of the essential subunit genes associated with retinoid/interferon–induced mortality–19, in response to apoptotic stimuli. This interaction, which is important for stabilizing the mitochondrial membrane potential, resulted in continued adenosine triphosphate production, which is critical for the successful completion of the virus' life cycle. Complex I targeting by a viral RNA represents a refined strategy to modulate the metabolic viability of the infected host cell.

24 June 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PLPaul Lehner
Paul Lehner
JKJaana T. Karttunen
Jaana T. Karttunen
GWGavin W. G. Wilkinson
Gavin W. G. Wilkinson
PCPeter Cresswell
Peter Cresswell
In its attempt to evade cytotoxic T cell recognition, human cytomegalovirus encodes several genes that target MHC class I molecules at different points in their assembly pathway. We show here that the human cytomegalovirus US6 gene encodes a 22-kDa glycoprotein that binds the transporter-associated with antigen processing (TAP)/class I complex and inhibits translocation of peptide from the cytosol to the endoplasmic reticulum. Major histocompatibility complex class I molecules are therefore unable to load TAP-dependent peptides, resulting in the retention of MHC class I molecules in the endoplasmic reticulum, with a consequent reduction in class I at the cell surface. Interferon-γ treatment of US6 transfected cells overcomes this inhibition of peptide translocation and restores class I at the cell surface to wild type levels. The functional consequence of TAP inhibition is that US6 transfected cells are unable to present endogenous antigen to cytotoxic T lymphocytes and are therefore resistant to cytotoxic T lymphocyte lysis.